Glycated albumin indicates peripheral diabetic neuropathy

被引:18
|
作者
Wang, Nana [1 ]
Guo, Chuanji [2 ]
Han, Ping [1 ]
Li, Tiegang [3 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Endocrinol, Shenyang 110004, Peoples R China
[2] China Med Univ, Shengjing Hosp, Hosp Adm Off, Shenyang 110004, Peoples R China
[3] China Med Univ, Shengjing Hosp, Emergency Dept, 36 Sanhao St, Shenyang 110004, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetic peripheral neuropathy; Glycated albumin; Hemoglobin A1c; Type 1 diabetes mellitus; GLYCEMIC CONTROL; RISK-FACTORS; AUTONOMIC NEUROPATHY; GLUCOSE EXCURSION; COMPLICATIONS; HEMOGLOBIN; PREVALENCE; MELLITUS; HBA1C;
D O I
10.1007/s00592-016-0900-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated associations between serum levels of glycated albumin (GA) and glycated hemoglobin (HbA1c) and the presence of diabetic peripheral neuropathy (DPN) in patients with type 1 diabetes mellitus (T1DM). Methods Between September 2009 and April 2015, we evaluated 314 patients with T1DM in the Endocrinology Department of Shengjing Hospital of China Medical University. We divided the patients into the DPN group (n = 72) and the non-DPN group (n = 242), on the basis of the presence of DPN. Results The DPN group had significantly higher GA values than the non-DPN group. After univariate logistic regression, we selected several factors for further analysis: HbA1c, GA, duration of T1DM, body mass index, smoking, hypertension, and the presence of diabetic complications, including nephropathy, retinopathy, and cardiovascular disease. We performed a multivariate logistic regression analysis to examine the association between the presence of DPN and each of these variables. We identified GA, HbA1c, hypertension, smoking, retinopathy, and cardiovascular disease as independent variables for indicating the presence of DPN. Results of a receiver operating characteristic curve analysis revealed that the area under the curve of GA (0.771) was larger than that of HbA1c (0.629). We defined the cutoff value of GA as 23.5 % (sensitivity 0.764, specificity 0.661) and the cutoff value of HbA1c as 8.45 % (sensitivity 0.667, specificity 0.595) for predicting DPN in patients with T1DM. Conclusions GA may be a better indicative marker of DPN in patients with T1DM than HbA1c.
引用
下载
收藏
页码:973 / 979
页数:7
相关论文
共 50 条
  • [41] PERIPHERAL NEUROPATHY IN DIABETIC BITCH
    MISSELBROOK, NG
    VETERINARY RECORD, 1987, 121 (12) : 287 - 287
  • [42] Treatment of Diabetic Peripheral Neuropathy
    Farhat, Nada M.
    Yezback, Krista L.
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2016, 12 (10): : 660 - 666
  • [43] Painful diabetic peripheral neuropathy
    Smith, Robert G.
    JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 2007, 97 (05) : 394 - 401
  • [44] Diabetic Peripheral Neuropathy in Youth
    Moser, Joanne T.
    Langdon, David R.
    JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES, 2013, 28 (04): : 415 - 417
  • [45] PERIPHERAL NEUROPATHY IN DIABETIC BITCH
    COLLYER, JH
    GRIPPER, PL
    VETERINARY RECORD, 1987, 121 (09) : 207 - 207
  • [46] TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY
    ROMAIN, LF
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (11): : 1037 - 1037
  • [47] THERAPY OF DIABETIC PERIPHERAL NEUROPATHY
    DIPALMA, JR
    GERIATRICS, 1982, 37 (07) : 43 - 46
  • [48] BIOTIN FOR DIABETIC PERIPHERAL NEUROPATHY
    KOUTSIKOS, D
    AGROYANNIS, B
    TZANATOSEXARCHOU, H
    BIOMEDICINE & PHARMACOTHERAPY, 1990, 44 (10) : 511 - 514
  • [49] Diabetic Peripheral Neuropathy and the Management of Diabetic Peripheral Neuropathic Pain
    Morales-Vidal, Sarkis
    Morgan, Christopher
    McCoyd, Mathew
    Hornik, Alejandro
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 145 - 153
  • [50] Glycated albumin to glycated hemoglobin ratio and mortality in diabetic patients on dialysis: a new association
    Hoshino, Junichi
    Abe, Masanori
    Hamano, Takayuki
    Hasegawa, Takeshi
    Wada, Atsushi
    Nakai, Shigeru
    Hanafusa, Norio
    Masakane, Ikuto
    Nitta, Kosaku
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (05) : 1309 - 1317